جستجوی مقالات مرتبط با کلیدواژه "lncrnas" در نشریات گروه "پزشکی"

This paper aimed to investigate the PI3K/Akt/mTOR signal-pathway regulator factor-related lncRNA signatures (PAM-SRFLncSigs), associated with regulators of the indicated signaling pathway in patients with lung adenocarcinoma (LUAD) undergoing immunotherapy.

In this retrospective study, we employed univariate Cox, multivariate Cox, and least absolute shrinkage and selection operator (LASSO) regression analyses to identify prognostically relevant long non-coding RNAs (lncRNAs), construct prognostic models, and perform Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. Subsequently, immunoassay and chemotherapy drug screening were conducted.Finally, the prognostic model was validated using the Imvigor210 cohort, and tumor stem cells were analyzed.

We identified seven prognosis-related lncRNAs (AC084757.3, AC010999.2, LINC02802, AC026979.2, AC024896.1, LINC00941 and LINC01312). We also developed prognostic models to predict survival in patients with LUAD. KEGG enrichment analysis confirmed association of LUAD with the PI3K/Akt/mTOR signaling pathway. In the analysis of immune function pathways, we discovered three good prognostic pathways (Cytolytic_activity, Inflammation-promoting, T_cell_co-inhibition) in LUAD. Additionally, we screened 73 oncology chemotherapy drugs using the "pRRophetic" algorithm.

Identification of seven lncRNAs linked to regulators of the PI3K/Akt/mTOR signaling pathway provided valuable insights into predicting the prognosis of LUAD, understanding the immune microenvironment and optimizing immunotherapy strategies.

Recurrent pregnancy loss (RPL) or recurrent miscarriage is the failure of pregnancy before 20-24 weeks that influencesaround 2-5% of couples. Several genetic, immunological, environmental and physical factors may influenceRPL. Although various traditional methods have been used to treat post-implantation failures, identifying the mechanismsunderlying RPL may improve an effective treatment. Recent evidence suggested that gene expression alterationspresented essential roles in the occurrence of RPL. It has been found that long non-coding RNAs (lncRNAs) playfunctional roles in pregnancy pathologies, such as recurrent miscarriage. lncRNAs can function as dynamic scaffolds,modulate chromatin function, guide and bind to microRNAs (miRNAs) or transcription factors. lncRNAs, by targetingvarious miRNAs and mRNAs, play essential roles in the progression or suppression of RPL. Therefore, targetinglncRNAs and their downstream targets might be a suitable strategy for diagnosis and treatment of RPL. In this review,we summarized emerging roles of several lncRNAs in stimulation or suppression of RPL.

Epidermal growth factor receptor (EGFR) is a cell surface protein that plays a vital role in regulating cell growth and division. However, certain tumors, such as colorectal cancer (CRC), can exhibit an overexpression of EGFR, resulting in uncontrolled cell growth and tumor progression. To address this issue, therapies targeting and inhibiting EGFR activity have been developed to suppress cancer growth. Nevertheless, resistance to these therapies poses a significant obstacle in cancer treatment. Recent research has focused on comprehending the underlying mechanisms contributing to anti-EGFR resistance and identifying new targets to overcome this striking challenge. Long noncoding RNAs (lncRNAs) are a class of RNA molecules that do not encode proteins but play pivotal roles in gene regulation and cellular processes. Emerging evidence suggests that lncRNAs may participate in modulating resistance to anti-EGFR therapies in CRC. Consequently, combining lncRNA targeting with the existing treatment modalities could potentially yield improved clinical outcomes. Illuminating the involvement of lncRNAs in anti-EGFR resistance mechanisms of cancer cells can provide valuable insights into the development of novel anti-EGFR therapies in several solid tumors.

The identification of long non-coding RNAs (lncRNAs) in the pathogenesis of acute myeloid leukemia (AML) has marked a new era in the molecular understating of the disease. This study investigated the correlation between the changes in the expression of lncRNAs, including HOTAIR, PVT-1, and CRNDE, and the alteration in the expression profile of FLT-3, c-Myc, STAT3, STAT5, and p27 in AML patients.

Blood samples were collected from forty-one newly diagnosed AML patients and ten healthy individuals to evaluate the expression levels of the study genes using qRT-PCR analysis. The probable correlation between the gene expressions was determined using Pearson’s correlation test.

The results showed that while there was a significant elevation in the expression of FLT3, c-Myc, STAT3, and HOTAIR, p27 expression remarkably diminished in AML patients compared to the control group. Also, a correlation was found between the expression of FLT-3 and p27 and the expression of HOTAIR and STAT3. It was assumed that FLT-3 had a role in increasing the proliferative and survival capacity of AML cells, at least partly, through c-Myc-mediated suppression of p27. Moreover, lncRNA HOTAIR showed to be involved in leukemia proliferation assumably by enhancing the expression of STAT3.

Overall, the results of gene profile analysis suggested that studying the expression of HOTAIR, FLT-3, c-Myc, STAT3, and p27 could be helpful to AML patients, and each of these genes could be a valuable target for pharmaceutic intervention.

Gastric cancer, known as one of the most frequent types of cancer, is associated with extensive mortality. Early detection could help to increase the survival rate of patients. Long non-coding RNAs (lncRNAs) as newly considered cancer probes were evaluated regarding as potential diagnostic candidates. LncRNAs NUTM2A-AS1, CTBP1-DT, THUMPD3-AS1, and LINC00667 were selected for wet-lab analysis based on literature review and pathway enrichment in-silico analysis. Four candidate lncRNAs in 70 gastric tissue samples including gastric tumors (n = 35) and paired Adjacent Normal Gastric Tissues (ANGTs) were collected for quantitative analysis. In the following, the expression level of four candidate lncRNAs was analyzed in gastric cancer samples compared to ANGTs and patient’s clinico-pathological data. Receiver Operating Characteristic (ROC) analysis was also performed to determine the diagnostic value of NUTM2A-AS1, CTBP1-DT, THUMPD3-AS1, and LINC00667 levels in tissue samples. Different pathways associated with NUTM2A-AS1, CTBP1-DT, THUMPD3-AS1, and LINC00667 lncRNAs were identified. The significantly elevated levels of all four lncRNAs were detected in GC tissue samples compared to ANGTs (P-value<0.05). The Aria Under Curve (AUC) of NUTM2A-AS1, CTBP1-DT, THUMPD3-AS1, and LINC00667 in the ROC curve were 0.825, 0.928, 0.688, and 0.649, respectively. Our results indicated that the expression levels of the four candidate lncRNAs were elevated in gastric tumors compared to ANGT samples. It might be helpful to illuminate the molecular mechanisms underlying gastric carcinogenesis which have been served as tumor-associated biomarkers for diagnosis.

The majority of ncRNAs are known as long non-coding RNAs (lncRNAs) whose length exceeds 200 nucleotides. H19, a lncRNA, is the transcription product of the H19 gene, an oncogene in breast cancer, and is highly expressed in cancer tissues compared with normal tissues. The expression level of H19 is associated with the oncogenesis, proliferation, invasion, metastasis, and drug resistance of breast cancer. H19 expression levels were detected in breast cancer plasma using qRT-Real-Time PCR assay in 50 breast cancer samples and 50 healthy control samples. The results showed that the expression of this gene in both the tissue and the plasma of patients increased compared to that of healthy individuals.

Long non-coding RNAs (lncRNAs) have been considered to be prospective biomarkers for diagnosing lung cancer due to the fundamental roles they hold in the regulating several cancer-related pathways.  Using the quantitative real-time polymerase chain reaction method, we evaluated the expression of CCAT2, UCA1, PANDA and GHET1 lncRNAs in 32 lung cancer tissue samples and their corresponding adjacent non-cancerous tissues (ANCTs) from lung cancer patients admitted to the Labbafi-Nejad Hospital from 2015 to 2016. No significant differences were found in the expression of lncRNAs within the tumoral and non-tumoral tissue samples. Bayesian Multilevel analysis showed no association between the expression of lncRNAs and the patient’s tumor node metastasis (TNM) stage following adjustments for age. Spearman correlation analysis revealed an inverse correlation between the expression of PANDA in tumoral tissues and age. Additionally, the difference in CCAT2 expression among the tumoral and non-tumoral tissues was inversely correlated with patients' age. Significant pairwise correlations were found between the expression of lncRNAs in both the tumoral and non-tumoral tissues. Despite the findings supporting a role for the lncRNAs, CCAT2, UCA1, PANDA and GHET1 in the pathogenesis of lung cancer, our data suggests no relationship for expression of these lncRNAs in lung cancer, questioning their potential as lung cancer biomarkers.

MicroRNAs (miRNAs) have crucial roles in cellular and molecular processes related to different malignancies including chronic lymphocytic leukemia (CLL). In recent years the most studies demonstrated that the expression of miR-95, alter in several diseases. Long non-coding RNAs (lncRNAs) a heterogeneous group of non-coding and regulatory RNAs. The present study investigated the association of miR-95 mRNA expression with CLL by quantitative real-time PCR for the first time. Sixty samples, including 30 CLL, and 30 healthy controls were sampled during a period of 4 months. The expression of miR-95 was determined by quantitative real-time PCR in peripheral blood mononuclear cells (PBMCs) of CLL patients in comparison with healthy subjects. Also, in silico pathway enrichment analysis performed on validated and predicted targets of miR-95 in several databases including miRecords and miRTarBase and predicted putative lncRNAs interplay with genes and miRNAs expression by mirwalk. The expression of miR-95 was found to be significantly reduced in CLL patients compared with healthy controls (P <0.005). Our findings suggested that miR-95 probably could be used as a new biomarker for early diagnosis of CLL patients, at least in Iranian patients. LncRNAs play a significant role in regulating cellular evolution, differentiation, and other processes. LncRNAs may serve as important regulators in tumorigenesis.